Expert Details
Targeted Therapies for Human Tumours
ID: 729289
Italy
Education
| Year | Degree | Subject | Institution |
|---|---|---|---|
| Year: 1988 | Degree: PhD | Subject: Oncology | Institution: Turin University |
| Year: 1983 | Degree: MD (Training Completed with Magna cum laude) | Subject: Medicine | Institution: Genoa University |
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2018 to Present | Employer: Undisclosed | Title: Professor in Translational Cancer Research | Department: |
Responsibilities:Available upon request. |
|||
| Years | Employer | Title | Department |
| Years: 2014 to Present | Employer: Undisclosed | Title: Chair in Cancer Research | Department: Biomedical Research Center |
Responsibilities:Teaching, Research, Clinical work |
|||
| Years | Employer | Title | Department |
| Years: 2014 to 2018 | Employer: Salford University | Title: Chair in Cancer Research | Department: |
Responsibilities:Available upon request. |
|||
| Years | Employer | Title | Department |
| Years: 2014 to 2018 | Employer: Royal Manchester University Hosp | Title: Consultant | Department: |
Responsibilities:Thoracic Medical Oncology and General Medicine |
|||
| Years | Employer | Title | Department |
| Years: 1999 to Present | Employer: Undisclosed | Title: Head of Dept General Medicine/Director Unit of Translational Research for Thoracic Medical Oncology | Department: Medicine |
Responsibilities:1999- to present:Head the Dept of General Medicine. Vercelli Teaching Hospital, Italian NHS, Vercelli, Joined with Oncology Dept Novara University (I) Scientific Director of the Lab of Clinical Oncology Local Health Authority Vercelli, Piedmont (I) General Medicine Dept with 25 acute beds, 20 beds of post acute beds 4 beds for day ward and 5 units (Internal Medicine, Respiratory Diseases, Medical Oncology, Gastro-enterology and Endocrinology) for the out- patients General duties: Clinical activity of internal medicine, medical oncology and respiratory medicine. Respiratory Endoscopic Procedures: diagnostic and interventional procedures Supervision and Resources management: Every year ca. 1500 patients are approximately discharged from the ward and 400-500 new out-patients come to the clinical units for clinical evaluation Supervisor and Responsible of the whole activity. Most of the activity for in-patients is spent with acute diseases or re-exacerbations of chronic or malignant disorders (Asthma, COPD, Ischemic Cardiac Diseases neoplastic and non neoplastic terminally ill patients etc) Expert is also directly and fully responsible of a busy unit of medical oncology aimed at the diagnosis, staging, treatment (chemotherapy) and follow-up of the most common solid tumours. He also arranged the start-up and has been leading a unit of Day Service exclusively aimed at the diagnosis and staging of patients with suspected cancer (One stop service). Moreover over the last seven years he has been personally running a unit of thoracic oncology for diagnosis and treatment of thoracic malignancies and set up a tertiary national referral centre for innovative translational therapies for Thoracic Malignancies. Expert leads the outpatients clinic for respiratory diseases and the lab of Pulmonary Function. This lab is also in charge of the second level evaluation of symptomatic workers with exposure to occupational airborne contaminants Clinical Management of the patients is decided through daily ward rounds and clinical meetings chaired by the candidate. The out patients are mainly managed through Day Service and Day Ward Chairman of Italian Association for study and Therapy of Malignant Mesothelioma: G.I.Me. www.gime.unige.it; www.gime.it) and Chair of the Buzzi Foundation SAB Expert coordinates and is directly in charge of the financial support of a broad range of preclinical/translational activities (across Europe and US) aimed at arranging a multidisciplinary approach to thoracic malignancies with particular interest in asbestos related tumours. Care of several patients with this aggressive cancer and treats them either with “traditional” or “innovative “ therapies according to the stage of the diseases and the ethical committees permits (ca 50 pts/yr) (Translational Research Activity aimed at pre-clinical and clinical testing of new drugs and diagnosis in human cancers). Currently PI of Clinical and preclinical research focused on Chemotherapy for Lung Cancer and new translational approaches for Thoracic malignancies: • Phase II clinical Trial with Bortezomib for Mesothelioma (UK, NI, Republic of Ireland, Belgium, Holland) • Phase II Clinical Trial Imatinib/Gemcitabine for Meso (Italy) • Phase II clinical Trial with Trabectedine for first line treatment of sarcomatous mesotehlioma and for second line of mixed, epithelial mesothelioma • Phase II Clinical Trial with anti Abs to CTLA4 for second line treatment for Meso Moreover am sub PI of the following • ICORG Phase III Adjuvant Breast Ca TC/Bevacizumab vs TC or TAC • ICORG Phase II Neo-Adjuvant Breast Ca TC/Trastuzumab vs TC/Lapatinib or TC/Trastuzumab/Lapatinib Lead Physician of the Lung Cancer MDT meeting. |
|||
Career Accomplishments
| Associations / Societies |
|---|
| Past Member of the Piedmont Oncology Board for the study of MM. Past Consultant for the Italian Foreign Affairs Ministry for the U.S.A-Italy. scientific cooperation; Consultant of the National Toxicology Commission; Member of the Committee of the Advanced Biotechnology Center (CBA) of Genoa Chairman of the Scientific Committee Fondazione Buzzi for Pleural Mesothelioma; Member of the Science Advisory Board Mesothelioma Applied Research Foundation; Expert Leader of European Respiratory Society for Chemotherapy and Novel Therapies for Pleural Mesothelioma; Italian Director of the International Mesothelioma Interest Group, International Board; Chairman of the Italian Group for the study and Therapy of Malignant Mesothelioma; EU Consultant of the European Research Commission for “Treatment Trials for Rare cancers;” Member of the Editorial Board of the Journal Oncology Reviews; Member of the Editorial Borad of ISRN Oncology; Peer reviewer for Cancer Research, Clin Cancer Res, European Respiratory Journal, PNAS, J of Cellular and Molecular Medicine, Lung cancer, Thorax, J of Occupational Medicine and Toxicology, PLOS, PLOSone; SOCIETIES FM Association of the Italian Chest Physicians FM7TF member European Respiratory Society FM Italian Society of Respiratory Medicine FM International Society of Translational Medicine FM/TF member IASLC |
| Professional Appointments |
|---|
| MEETINGS as an Invited Speaker Chairman (last five years) |
| Awards / Recognition |
|---|
| HONORS -Past Member of the Piedmont Oncology Board for the study of MM. Past Consultant for the Italian Foreign Affairs Ministry for the U.S.A-Italy. scientific cooperation -Consultant of the National Toxicology Commission -Member of the Committee of the Advanced Biotechnology Center (CBA) of Genoa -Chairman of the Scientific Committee Fondazione Buzzi for Pleural Mesothelioma -Member of the Science Advisory Board Mesothelioma Applied Research Foundation (USA) - Expert Leader of European Respiratory Society for “Chemotherapy and Novel Therapies for Pleural Mesothelioma” -Member of the European TF for the standardization of the procedures in Thoracic Oncology -Member of the IASLC TF for new therapeutic targets for malignant pleural mesothelioma -Italian Director of the International Mesothelioma Interest Group International Board -Chairman of the Italian Group for the study and Therapy of Malignant Mesothelioma -2008. Winner of the Italian National Award for the the Research on Asbestos Related Tumours granted by the Italian National Association for Labour EU Consultant of the European Research Commission for “Treatment Trials for Rare cancers” 2014. Winner of the prize “Scientist of the Year” bestowed by Piedmont College of Journalists |
| Medical / Professional |
|---|
| M.D. training completed with Magna cum laude. Genoa University Post degree training in General Medicine meeting the standards laid down in Article 23 of the European Medical Directive 93/16/ EEC (GTP equivalent) and MRCP (CCT equivalent in Respiratory Medicine Genoa University Post degree Training in Medical Oncology Ph.D in Oncology programme completed . Turin University Higher Medical Training Qualification in General Medicine (CCT equivalent) Article 56 DPR Italian Law . Entitlement to Lead a Dept of General Medicine and Subspecialties RCPI Appraised Specialist Registration for Medical Oncology PhD equivalent Art 6 Equivalencies ERC |
| Publications and Patents Summary |
|---|
| He has approximately 130 indexd publications on PubMed. |
Additional Experience
| Expert Witness Experience |
|---|
| Hearing by Italian government for environmental human tumours. |
| Training / Seminars |
|---|
| He has taught several courses and delevered many conferences over the last several years. |
Language Skills
| Language | Proficiency |
|---|---|
| English | |
| Italian |